Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (31-40 of 216) with videos related to

Pageof 22
Sort By:
Cell|February 5, 2022
Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeGolnaz Morad, Beth A Helmink, Padmanee Sharma, et al.
Nature Reviews. Cancer|October 25, 2011
Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsPadmanee Sharma, Klaus Wagner, Jedd D Wolchok, et al.
Trends in Immunology|October 4, 2012
Advances in the development of cancer immunotherapiesJianjun Gao, Chantale Bernatchez, Padmanee Sharma, et al.
Pharmacotherapy|September 20, 2011
Cancer immunotherapy: sipuleucel-T and beyondAimee E Hammerstrom, Diana H Cauley, Bradley J Atkinson, et al.
Journal for Immunotherapy of Cancer|January 26, 2022
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapiesOlivier Michielin, Aly-Khan Lalani, Caroline Robert, et al.
Leukemia & Lymphoma|July 7, 2017
The emerging role of immune checkpoint based approaches in AML and MDSPrajwal Boddu, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Advances in Experimental Medicine and Biology|March 22, 2017
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AMLLucia Masarova, Hagop Kantarjian, Guillermo Garcia-Mannero, et al.
Cancer Immunity|May 28, 2008
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapyJingjing Sun, Jade Schiffman, Anitha Raghunath, et al.
Cancer Immunity|June 27, 2007
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancerChrysoula I Liakou, Sowmita Narayanan, Derek Ng Tang, et al.
Cancer Immunology Research|August 6, 2014
Cancer immunotherapy highlights from the 2014 ASCO MeetingLauren C Harshman, Charles G Drake, Jennifer A Wargo, et al.
Pageof 22

Showing results (31-40 of 216) with videos related to

Sort By:
Pageof 22
Cell|February 5, 2022
Hallmarks of response, resistance, and toxicity to immune checkpoint blockadeGolnaz Morad, Beth A Helmink, Padmanee Sharma, et al.
Nature Reviews. Cancer|October 25, 2011
Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsPadmanee Sharma, Klaus Wagner, Jedd D Wolchok, et al.
Trends in Immunology|October 4, 2012
Advances in the development of cancer immunotherapiesJianjun Gao, Chantale Bernatchez, Padmanee Sharma, et al.
Pharmacotherapy|September 20, 2011
Cancer immunotherapy: sipuleucel-T and beyondAimee E Hammerstrom, Diana H Cauley, Bradley J Atkinson, et al.
Journal for Immunotherapy of Cancer|January 26, 2022
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapiesOlivier Michielin, Aly-Khan Lalani, Caroline Robert, et al.
Leukemia & Lymphoma|July 7, 2017
The emerging role of immune checkpoint based approaches in AML and MDSPrajwal Boddu, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Advances in Experimental Medicine and Biology|March 22, 2017
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AMLLucia Masarova, Hagop Kantarjian, Guillermo Garcia-Mannero, et al.
Cancer Immunity|May 28, 2008
Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapyJingjing Sun, Jade Schiffman, Anitha Raghunath, et al.
Cancer Immunity|June 27, 2007
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancerChrysoula I Liakou, Sowmita Narayanan, Derek Ng Tang, et al.
Cancer Immunology Research|August 6, 2014
Cancer immunotherapy highlights from the 2014 ASCO MeetingLauren C Harshman, Charles G Drake, Jennifer A Wargo, et al.
Pageof 22